All In Biotech

Drug Trial Radar · NCT00068029

Pegvisomant And Sandostatin LAR Combination Study

A Randomized, Parallel Group, Three-Arm Study To Evaluate Treatment With A Combination Of Pegvisomant Plus Sandostatin Lar, Pegvisomant (Alone), And Sandostatin Lar (Alone) In Patients With Acromegaly

Last checked: Nov 20, 2026Latest source record: Apr 7, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

75

Actual

Start

Oct 2003

Primary completion

Not stated

Study completion May 2006

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Sep 5, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.

Conditions

  • Acromegaly

Interventions

  • Pegvisomant/ Sandostatin LARDrug

  • Sandostatin LARDrug

  • PegvisomantDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects experiencing treatment-emergent adverse events across the duration fo the study

Locations

33 sites in 12 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Boston, Massachusetts

  • Pfizer Investigational Site

    Chapel Hill, North Carolina

  • Pfizer Investigational Site

    Charlottesville, Virginia

  • Pfizer Investigational Site

    Darlinghurst, New South Wales, Australia

  • Pfizer Investigational Site

    Fitzroy, Victoria, Australia

  • Pfizer Investigational Site

    Fizroy, Victoria, Australia

  • Pfizer Investigational Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Pfizer Investigational Site

    São Paulo, São Paulo, Brazil

  • Pfizer Investigational Site

    Halifax, Nova Scotia, Canada

  • Pfizer Investigational Site

    Halifax, Nova Scotia, Canada

  • Pfizer Investigational Site

    Toronto, Ontario, Canada

  • Pfizer Investigational Site

    Montpellier, France

  • Pfizer Investigational Site

    Nice, France

  • Pfizer Investigational Site

    Berlin, Germany

  • Pfizer Investigational Site

    Dresden, Germany

  • Pfizer Investigational Site

    Hanover, Germany

  • Pfizer Investigational Site

    Genova, Italy

  • Pfizer Investigational Site

    Messina, Italy

  • Pfizer Investigational Site

    Milan, Italy

  • Pfizer Investigational Site

    Torino, Italy

  • Pfizer Investigational Site

    Mexico City, Mexico City, Mexico

  • Pfizer Investigational Site

    Col La Raza, Mexico DF, Mexico

  • Pfizer Investigational Site

    Nijmegen, Netherlands

  • Pfizer Investigational Site

    Oslo, Norway

  • Pfizer Investigational Site

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Pfizer Investigational Site

    Madrid, Madrid, Spain

  • Pfizer Investigational Site

    Leeds, United Kingdom

  • Pfizer Investigational Site

    London, United Kingdom

  • Pfizer Investigational Site

    London, United Kingdom

  • Pfizer Investigational Site

    Manchester, United Kingdom

  • Pfizer Investigational Site

    Oxford, United Kingdom

  • Pfizer Investigational Site

    Belfast, Antrim, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.